索诺马制药公司现在在美国经林业发展局登记后出售低氯酸面部喷雾剂,作为化妆品。 Sonoma Pharmaceuticals now sells hypochlorous acid facial sprays as cosmetics in the U.S. after FDA registration.

索诺玛制药公司已注册其制造设施,并将基于Microcyn的面部喷雾剂列入FDA的MoCRA, 使其能够在美国作为化品销售稳定型低酸产品. Sonoma Pharmaceuticals has registered its manufacturing facility and listed a Microcyn-based facial spray under the FDA’s MoCRA, enabling it to market stabilized hypochlorous acid products as cosmetics in the U.S. 到2030年,这项行动将其投资组合扩大到医疗设备之外,进入了日益增长的400亿美元的美国皮肤护理市场。 The move expands its portfolio beyond medical devices into the growing $40 billion U.S. skincare market by 2030. 该公司的专利微晶技术已在55个以上的国家使用,以治疗轻微的皮肤刺激闻名,现有510(k)条清除的伤口护理和皮肤病理产品支持这一技术。 The company’s patented Microcyn technology, already used in over 55 countries, is known for treating minor skin irritations and is supported by existing 510(k)-cleared products in wound care and dermatology. 通过注册,该公司将建立在目前已获得FDA注册的医疗器械设施基础上,并加强其在护肤和动物健康领域的存在. The registration builds on its current FDA-registered medical device facility and strengthens its presence in skincare and animal health.